Literature DB >> 7041546

C-reactive protein and the acute phase response.

H Gewurz, C Mold, J Siegel, B Fiedel.   

Abstract

Since its discovery approximately fifty years ago, CRP has been recognized as the prototype acute phase reactant. Now appreciated as a trace serum protein that elevates markedly in concentration in association with inflammation and tissue necrosis, CRP also has been found deposited at sites of cell injury. Together with its long appreciated ability to initiate precipitation, agglutination, and capsular swelling reactions, these considerations early led to the surmise that CRP may play a role in the host adaptive response. Studies of its binding specificities have indicated that CRP has reactivity with (a) phosphocholine and phosphate esters, and hence with lipids widely distributed in mammalian and microbial cells; and (b) with multiple widely distributed polycations, including those derived from leukocyte granules. Interaction with either of these ligands has been shown to alter CRP in such a way that it can bring about activation of the complement system with generation of all the known C-dependent reactivities, including component consumption, adherence, phagocytosis, and cytolysis. Similarly, modified CRP has been shown to react with the FcR or a closely related receptor of monocytes and lead to phagocytosis, to react with certain FcR-bearing lymphocytes, and to activate the platelet. Thus, CRP shares with immunoglobulins the ability to initiate multiple effector functions that have been associated with the inflammatory response, as well as to bring about primary recognition reactions. Obviously CRP-ligand reactions would be favored during intervals of acute inflammation and tissue necrosis, when larger amounts of CRP are available. Therefore, in addition to serving as a diagnostic aid for the presence of inflammatory and necrotic processes, elevated levels of CRP may well provide an important component of the nonspecific host mechanisms, particularly in the early stages following inflammatory stimuli. Inquiries into the structure and function of CRP indicated an unexpected relationship of this molecule to an amyloid-related protein. The amyloid P component shows remarkable structural similarity to CRP and also exhibits calcium-dependent reactivity with widely distributed ligands; those appreciated to date have mainly involved polysaccharides derived from fungi and natural products. While the only relationship of SAP to an immune-related effector system found to date is reactivity with altered C3, it nonetheless seems plausible that SAP, which like CRP recognizes certain microbial and altered host molecules and has the potential of activating a host effector system at the recognition site. Further inquiry into the structure and functional relationships of these molecules, which are broadly distributed through the vertebrates, should help to reveal the role that CRP and other acute phase proteins have in the body economy and provide additional insights to the understanding of body defense mechanisms in inflammatory, repair, and defense processes generally.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7041546

Source DB:  PubMed          Journal:  Adv Intern Med        ISSN: 0065-2822


  68 in total

1.  Identification of diagnostic biomarkers for infection in premature neonates.

Authors:  Stephen F Kingsmore; Neil Kennedy; Henry L Halliday; Jennifer C Van Velkinburgh; Shengiang Zhong; Vanessa Gabriel; Judith Grant; William D Beavis; Velizar T Tchernev; Lorah Perlee; Serguei Lejnine; Brian Grimwade; Martin Sorette; J David M Edgar
Journal:  Mol Cell Proteomics       Date:  2008-07-13       Impact factor: 5.911

Review 2.  Complement: an overview for the clinician.

Authors:  Juan Carlos Varela; Stephen Tomlinson
Journal:  Hematol Oncol Clin North Am       Date:  2015-04-04       Impact factor: 3.722

3.  Platelet response to aggregated C-reactive protein: fibrinogen-dependent and independent signals.

Authors:  B A Fiedel
Journal:  Immunology       Date:  1988-01       Impact factor: 7.397

4.  A shrimp C-type lectin inhibits proliferation of the hemolymph microbiota by maintaining the expression of antimicrobial peptides.

Authors:  Xian-Wei Wang; Ji-Dong Xu; Xiao-Fan Zhao; Gerardo Raul Vasta; Jin-Xing Wang
Journal:  J Biol Chem       Date:  2014-03-11       Impact factor: 5.157

5.  C-reactive protein-mediated complement activation in polymyalgia rheumatica and other systemic inflammatory diseases.

Authors:  P Vaith; G M Hänsch; H H Peter
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

6.  Correlation of serum opsonins with in vitro phagocytosis of Streptococcus pneumoniae.

Authors:  D S Chudwin; S G Artrip; A Korenblit; G Schiffman; S Rao
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

7.  Elevated Values of C-Reactive Protein Induced by Imported Infectious Diseases: A Controlled Cross-Sectional Study of 11,079 Diseased German Travelers Returning from the Tropics and Subtropics.

Authors:  Karl-Heinz Herbinger; Ingrid Hanus; Mirjam Schunk; Marcus Beissner; Frank von Sonnenburg; Thomas Löscher; Gisela Bretzel; Michael Hoelscher; Hans Dieter Nothdurft; Kristina Lydia Huber
Journal:  Am J Trop Med Hyg       Date:  2016-08-15       Impact factor: 2.345

8.  Generation of thromboxane A2 and aorta-contracting activity from platelets stimulated with modified C-reactive protein.

Authors:  R M Simpson; A Prancan; J M Izzi; B A Fiedel
Journal:  Immunology       Date:  1982-09       Impact factor: 7.397

9.  In vivo studies of serum C-reactive protein turnover in rabbits.

Authors:  M Chelladurai; S S Macintyre; I Kushner
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

10.  Disease-associated glycosylated molecular variants of human C-reactive protein activate complement-mediated hemolysis of erythrocytes in tuberculosis and Indian visceral leishmaniasis.

Authors:  Waliza Ansar; Sumi Mukhopadhyay; S K Hasan Habib; Shyamasree Basu; Bibhuti Saha; Asish Kumar Sen; C N Mandal; Chitra Mandal
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.